ESALY Stock - Eisai Co., Ltd.
Unlock GoAI Insights for ESALY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $756.23B | $645.94B | $695.62B | $642.83B | $600.05B |
| Gross Profit | $581.39B | $484.63B | $519.93B | $458.34B | $398.80B |
| Gross Margin | 76.9% | 75.0% | 74.7% | 71.3% | 66.5% |
| Operating Income | $58.39B | $51.77B | $125.50B | $86.15B | $77.21B |
| Net Income | $45.72B | $42.12B | $121.77B | $63.39B | $51.84B |
| Net Margin | 6.0% | 6.5% | 17.5% | 9.9% | 8.6% |
| EPS | $159.44 | $146.94 | $424.77 | $221.12 | $724.71 |
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
ESALYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2022 | Dec 31, 2022 | — | $0.25 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.25 | — | — |
Q4 2022 | Nov 6, 2022 | — | $0.09 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.09 | — | — |
Q3 2022 | Aug 4, 2022 | — | $0.72 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.72 | — | — |
Q2 2022 | May 12, 2022 | — | $-0.40 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.40 | — | — |
Q1 2022 | Feb 2, 2022 | — | $0.40 | — | — |
Q4 2021 | Oct 31, 2021 | — | $0.13 | — | — |
Q3 2021 | Aug 3, 2021 | — | $1.32 | — | — |
Q2 2021 | May 11, 2021 | — | $-0.10 | — | — |
Q1 2021 | Feb 2, 2021 | — | $0.65 | — | — |
Q4 2020 | Nov 4, 2020 | — | $0.05 | — | — |
Q3 2020 | Aug 2, 2020 | — | $0.79 | — | — |
Q2 2020 | May 12, 2020 | — | $1.57 | — | — |
Q1 2020 | Jan 30, 2020 | — | $1.49 | — | — |
Q4 2019 | Oct 29, 2019 | — | $0.17 | — | — |
Q3 2019 | Jul 30, 2019 | — | $0.70 | — | — |
Q2 2019 | May 12, 2019 | — | $0.74 | — | — |
Latest News
Frequently Asked Questions about ESALY
What is ESALY's current stock price?
What is the analyst price target for ESALY?
What sector is Eisai Co., Ltd. in?
What is ESALY's market cap?
Does ESALY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ESALY for comparison